Vericel Corp (VCEL) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn domains. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts for skin replacement. The company is also developing ixmyelocel-T technology, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM). It has manufacturing facilities in Cambridge, Massachusetts; Ann Harbour, Michigan and Kastrup, Denmark. The company sells its products through cell therapy specialists. Vericel is headquartered in Cambridge, the US.

Vericel Corp (VCEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 4
List of Figures 4
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vericel Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vericel Corp, Medical Devices Deals, 2012 to YTD 2018 9
Vericel Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vericel Corp, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Innovative Cellular Therapeutics Enters into Licensing Agreement with Vericel 11
Equity Offering 12
Vericel Raises USD74.8 Million in Public Offering of Shares 12
Vericel Raises USD19.6 Million in Public Offering of Shares 14
Aastrom Biosciences Raises USD15 Million in Private Placement of Shares 15
Aastrom Biosciences Raises USD40 Million in Public Offering of Shares 16
Aastrom Biosciences Completes Public Offering Of Shares For US$9 Million 18
Aastrom Biosciences Completes Private Placement Of Series B Convertible Preference Stock For US$40 Million 19
Acquisition 20
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 20
Vericel Corp - Key Competitors 21
Vericel Corp - Key Employees 22
Vericel Corp - Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 06, 2018: Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance 24
May 08, 2018: Vericel Reports First Quarter 2018 Financial Results 26
Mar 05, 2018: Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance 28
Nov 07, 2017: Vericel Reports Third-Quarter 2017 Financial Results 30
Aug 09, 2017: Vericel Reports Second-Quarter 2017 Financial Results 31
May 10, 2017: Vericel Reports First-Quarter 2017 Financial Results 33
Mar 10, 2017: Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results 35
Corporate Communications 37
Aug 20, 2018: Vericel names Jonathan Hopper as chief medical officer 37
Apr 10, 2017: Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs 38
Product Approvals 39
Feb 21, 2017: Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy 39
Other Significant Developments 40
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List Of Tables


Vericel Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vericel Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vericel Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Vericel Corp, Medical Devices Deals, 2012 to YTD 2018 9
Vericel Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Innovative Cellular Therapeutics Enters into Licensing Agreement with Vericel 11
Vericel Raises USD74.8 Million in Public Offering of Shares 12
Vericel Raises USD19.6 Million in Public Offering of Shares 14
Aastrom Biosciences Raises USD15 Million in Private Placement of Shares 15
Aastrom Biosciences Raises USD40 Million in Public Offering of Shares 16
Aastrom Biosciences Completes Public Offering Of Shares For US$9 Million 18
Aastrom Biosciences Completes Private Placement Of Series B Convertible Preference Stock For US$40 Million 19
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 20
Vericel Corp, Key Competitors 21
Vericel Corp, Key Employees 22
Vericel Corp, Other Locations 23
Vericel Corp, Subsidiaries 23

List Of Figures


Vericel Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vericel Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vericel Corp, Medical Devices Deals, 2012 to YTD 2018 9

Vericel Corp (VCEL) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn domains. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the

USD 250 View Report

Vericel Corporation Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Vericel Corporation Company Profile is a detailed strategic and analytical report on Vericel Corporation. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Vericel Corporation Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Vericel Corporation Company Profile is a detailed strategic and analytical report on Vericel Corporation. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Vericel Corp (VCEL) - Medical Equipment - Deals and Alliances Profile.

Vericel Corp (Vericel) formerly Aastrom Biosciences, Inc. is a medical device company that develops patient-specific expanded cellular therapies to repair and regenerate damaged tissue for the treatment of severe, chronic

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request